Gianluca Mucciolo

Dr. Gianluca Mucciolo

Università degli Studi di Torino
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GMGianluca Mucciolo
Gianluca Mucciolo
CCClaudia Curcio
Claudia Curcio
CRCecilia Roux
Cecilia Roux
WLWanda Y. Li
Wanda Y. Li
MCMichela Capello
Michela Capello
Paola CappelloPaola Cappello
Paola Cappello
A hallmark of cancer, including pancreatic ductal adenocarcinoma (PDA), is a massive stromal and inflammatory reaction. Many efforts have been made to identify the anti- or protumoral role of cytokines and immune subpopulations within the stroma. Here, we investigated the role of interleukin-17A (IL17A) and its effect on tumor fibroblasts and the tumor microenvironment. We used a spontaneous PDA mouse model (KPC) crossed to IL17A knockout mice to show an extensive desmoplastic reaction, without impaired immune infiltration. Macrophages, especially CD80+ and T cells, were more abundant at the earlier time point. In T cells, a decrease in FoxP3+ cells and an increase in CD8+ T cells were observed in KPC/IL17A−/− mice. Fibroblasts isolated from IL17A+/+ and IL17A−/− KPC mice revealed very different messenger RNA (mRNA) and protein profiles. IL17A−/− fibroblasts displayed the ability to restrain tumor cell invasion by producing factors involved in extracellular matrix remodeling, increasing T cell recruitment, and producing higher levels of cytokines and chemokines favoring T helper 1 cell recruitment and activation and lower levels of those recruiting myeloid/granulocytic immune cells. Single-cell quantitative PCR on isolated fibroblasts confirmed a very divergent profile of IL17A-proficient and -deficient cells. All these features can be ascribed to increased levels of IL17F observed in the sera of IL17A−/− mice, and to the higher expression of its cognate receptor (IL17RC) specifically in IL17A−/− cancer-associated fibroblasts (CAFs). In addition to the known effects on neoplastic cell transformation, the IL17 cytokine family uniquely affects fibroblasts, representing a suitable candidate target for combinatorial immune-based therapies in PDA. Significance There are controversial data about the protumoral role of pancreatic cancer stroma, and dissecting multiple aspects will help to develop effective tailored therapies. Interleukin-17A (IL17A) has been reported to accelerate pancreatic acinar–ductal metaplasia, be important for maintaining stem-like cancer cells, and recruit immunosuppressive granulocytes into the tumor. Here we unveil a relationship between IL17A and pancreatic stromal cells, which strongly modifies their gene and protein expression profiles. Ablation of IL17A, in fact, modifies the cytokines/factors released by tumor fibroblasts by limiting T cell immunosuppression. IL17A inhibition may represent an important tool for designing novel combined therapeutic approaches.

1 January 2020 in Cancer Drug Resistance
Verified
Journal Article
Open access
GMGianluca Mucciolo
Gianluca Mucciolo
CRCecilia Roux
Cecilia Roux
ASAlessandro Scagliotti
Alessandro Scagliotti
SBSilvia Brugiapaglia
Silvia Brugiapaglia
FNFrancesco Novelli
Francesco Novelli
Paola CappelloPaola Cappello
Paola Cappello
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.

21 January 2025 in Cancer Research
Verified
Journal Article
Open access
ELEloise G. Lloyd
Eloise G. Lloyd
MJMuntadher Jihad
Muntadher Jihad
JMJudhell S. Manansala
Judhell S. Manansala
WLWenlong Li
Wenlong Li
PCPriscilla S.W. Cheng
Priscilla S.W. Cheng
GBGiulia Biffi
Giulia Biffi
Pancreatic ductal adenocarcinoma (PDAC) contains an extensive stroma that modulates response to therapy, contributing to the dismal prognosis associated with this cancer. Evidence suggests that PDAC stromal composition is shaped by mutations within malignant cells, but most previous work has focused on preclinical models driven by KrasG12D and mutant Trp53. Elucidation of the contribution of additional known oncogenic drivers, including KrasG12V mutation and Smad4 loss, is needed to increase the understanding of malignant cell–stromal cell cross-talk in PDAC. In this study, we used single-cell RNA sequencing to analyze the cellular landscape of Trp53-mutant mouse models driven by KrasG12D or KrasG12V, in which Smad4 was wild type or deleted. KrasG12DSmad4-deleted PDAC developed a fibro-inflammatory rich stroma with increased malignant JAK/STAT cell signaling and enhanced therapeutic response to JAK/STAT inhibition. SMAD4 loss in KrasG12V PDAC differently altered the tumor microenvironment compared with KrasG12D PDAC, and the malignant compartment lacked JAK/STAT signaling dependency. Thus, malignant cell genotype affects cancer cell and stromal cell phenotypes in PDAC, directly affecting therapeutic efficacy. Significance: SMAD4 loss differentially impacts malignant cell–stromal cell signaling and treatment sensitivity of pancreatic tumors driven by KRASG12D or KRASG12V, highlighting the importance of understanding genotype–phenotype relationships for precision therapy.

16 September 2024 in Cancer Research
Verified
Journal Article
Closed access
GMGianluca Mucciolo
Gianluca Mucciolo
WLWenlong Li
Wenlong Li
GBGiulia Biffi
Giulia Biffi
Our knowledge of the origins, heterogeneity, and functions of cancer-associated fibroblasts (CAF) in pancreatic ductal adenocarcinoma (PDAC) has exponentially increased over the last two decades. This has been facilitated by the implementation of new models and single-cell technologies. However, a few key studies preceded the current exciting times in CAF research and were fundamental in initiating the investigation of CAFs and of their roles in PDAC. With their study published in Cancer Research in 2008, Hwang and colleagues have been first to successfully isolate and immortalize human pancreatic stellate cells (HPSC) from PDAC tissues. This new tool allowed them to probe the roles of CAFs in PDAC as never done before. By performing complementary in vitro and in vivo analyses, the authors demonstrated the involvement of HPSCs in PDAC malignant cell proliferation, invasion, and therapy resistance. Here, we leverage that seminal study as a framework to discuss the advances made over the last 16 years in understanding the complexity and central roles of CAFs in PDAC progression. See related article by Hwang and colleagues, Cancer Res 2008;68:918–26

10 March 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
CRCecilia Roux
Cecilia Roux
GMGianluca Mucciolo
Gianluca Mucciolo
JKJoanna Kopecka
Joanna Kopecka
Francesco NovelliFrancesco Novelli
Francesco Novelli
Chiara RigantiChiara Riganti
Chiara Riganti
Paola CappelloPaola Cappello
Paola Cappello
Background: Interleukin (IL)17A is a member of the IL17 cytokine family, which is released by both immune and non-immune cells such as tumor and stromal cells into the tumor microenvironment. IL17 receptors are also widely expressed in different type of cells. Among all the members, IL17A is the most controversial in regulating tumor immunity. Here, we investigated how IL17A inhibition modulated macrophage differentiation and metabolism in the presence or absence of gemcitabine. Gemcitabine is the gold standard drug for treating pancreatic cancer and can increase macrophage antitumoral activities. Results: We observed some unique features of macrophages polarized in the absence of IL17A, in terms of RNA and protein expression of typical phenotypic markers, and we demonstrated that this paralleled specific changes in their metabolism and functions, such as the induction of an antitumor response. Interestingly, these features were almost maintained or enhanced when macrophages were treated with gemcitabine. We also demonstrated that the anti-IL17A antibody effectively reproduced features of macrophages derived from IL17A knock-out mice. Conclusion: Overall, we provide a proof-of-concept that combining an anti-IL17A antibody with gemcitabine may represent an effective strategy to modulate macrophages and enhance the anti-tumor response, especially in pancreatic cancer where gemcitabine is widely used.

17 March 2025 in South East European Journal of Immunology
Verified
Journal Article
Open access
PDF file
Luca VannucciLuca Vannucci
Luca Vannucci
LRL Rajsiglova
L Rajsiglova
DSD Stakheev
D Stakheev
PLP Lukac
P Lukac
PTP Tenti
P Tenti
DSD Smrz
D Smrz
Cancer is a complex illness with local to systemic expression. Cancer cells in relation with the constitutive components of the tissue from which they develop and the immune system elements, that interact with them to ablate the cancer cells and promote tissue repair, form the tumor microenvironment. The interactions between all these elements decide the tumor evolution either toward its elimination (inflammation, immune recognition and direct cytotoxicity) or its establishment and progression (inversion of the immune response, chronic and smoldering inflammation, immune cell exhaustion and establishment of an immune suppressive and tissue remodeling environment). The alteration of the tissue collagen scaffold influenced by the immune environment continuous modifications collaborates to impede adequate access to immune cells and drugs and solicitate epithelial to mesenchymal transition allowing metastatic cell behavior. Under these conditions, the altered immune environment can bias the efficacy of the treatments and favor the tumor heterogeneity. Many therapeutic approaches were developed, from surgery to chemo- and radiotherapy until the recent advances in immunotherapy. However, if the therapeutic approach is systemic, sensible side effects can accompany the treatment because of the involvement also of non-tumoral tissues. Therefore, from the last years of the XX century, a progressive interest and improvement in technical possibilities started to focus on targeting therapies using monoclonal antibodies (e.g. against cellular pathways, growth-factors, immune check-point molecules) and/or organic/inorganic nano-constructs (e.g. ferritin-based, iron-based nanoparticles) studied for directly affect the cancer cells or other microenvironment components (immune cells). Focusing the intervention to the pathological component and selectively foster the anticancer response is the aim of modern oncology. In this presentation, we will highlight some of our observations done on components of the microenvironment favoring the tumor escape and our experience of tumor targeting by nanoparticles in experimental models looking to achieve more tumor and antigen specific treatments for enhancing the anti-cancer immune response, possibly with a patient-tailored approach. Acknowledgements: we thanks the support by Institutional Grant RVO 61388971 (CZ), GAAV IAA500200917 (CZ), AZV NU23-08-00071 (CZ), MEYS CR (Large RI Project LM2018129 Czech-BioImaging), ERDF (project No. CZ.02.1.01/0.0/0.0/18_046/0016045) and the project National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102) - Funded by the European Union –Next Generation EU, Generali Ceska Pojistovna Foundation (CZ), UniCredit Bank (CZ), SIAD s.r.o. (ITA/CZ), GITCO s.r.o (CZ), CONTAS s.r.o (CZ), CAMIC a.s. (CZ)